Comparison of the efficacy and tolerability of gefitinib with pemetrexed maintenance after first-line platinum-based doublet chemotherapy in advanced lung adenocarcinoma: single-center experience
| Autor: | Xiaolong Cao, Fuxi Huang, Liping Lin, Juanjuan Zhao, Yan He, Jianjun Han, Jiazhu Hu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Oncology
medicine.medical_specialty medicine.medical_treatment Population maintenance therapy gefitinib 03 medical and health sciences 0302 clinical medicine Gefitinib Maintenance therapy Internal medicine medicine Pharmacology (medical) 030212 general & internal medicine Epidermal growth factor receptor education pemetrexed neoplasms Original Research education.field_of_study Chemotherapy biology business.industry Hazard ratio lung adenocarcinoma respiratory tract diseases Pemetrexed Tolerability 030220 oncology & carcinogenesis biology.protein business medicine.drug |
| Zdroj: | OncoTargets and therapy |
| ISSN: | 1178-6930 |
| Popis: | PURPOSE Both gefitinib and pemetrexed maintenance were effective therapies for advanced lung adenocarcinoma, but which is better is unclear. For patients with advanced lung adenocarcinoma, we have no idea whether we should choose gefitinib or pemetrexed maintenance in clinical practice. Here, we assessed the efficacy and tolerability of gefitinib versus pemetrexed maintenance in these patients. PATIENTS AND METHODS A total of 101 patients were identified and divided into gefitinib (n=53) or pemetrexed (n=48) maintenance. Epidermal growth factor receptor (EGFR) status of tumors was analyzed in 67 patients. Disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) were compared between the two groups. RESULTS The results showed that DCR (79.2% vs 75%, P=0.642) was similar between gefitinib and pemetrexed groups. The PFS of gefitinib was significantly longer than that of pemetrexed (8 months vs 5.4 months, hazard ratio [HR]: 0.520, 95% confidence interval [CI]: 0.341-0.791, P=0.002); however, the OS was similar (19.9 months vs 18.8 months, HR: 1.006, 95% CI: 0.664-1.525, P=0.977). In EGFR mutation-positive patients, PFS was significantly longer in gefitinib (12 months vs 5.4 months; HR: 0.158, 95% CI: 0.074-0.333, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|